Abdelmonem Awad Hegazy
ID
 Email src
Department of Medical Biotechnology, College of Biotechnology, Misr University for Science and Technology, Giza, Egypt
Received: 15 July 2021 / Accepted: 26 July 2021 / Published: 30 September 2021

Abstract

Cite

Hegazy AA. Ivermectin for COVID-19 prophylaxis. Eur J Clin Exp Med. 2021;19(3):280–282. doi: 10.15584/ejcem.2021.3.15

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited